Advertisement

Topics

Latest "Galectin Therapeutics" News Stories

11:35 EDT 24th June 2017 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 8,600+

Extremely Relevant

Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Updated: 04052017] Prices from USD $350

Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Galectin Therapeutics Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions un...


Galectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2

The Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NORCROSS, Ga., Jan. 30, 2017 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D, president, chief executive officer a...

Galectin Therapeutics: 1 More Shot To Get It Right?


Relevant

Galectin Therapeutics (GALT) Investor Presentation - Slideshow

Galectin Therapeutics: Serendipity In Psoriasis, Strength In NASH

Galectin Therapeutics (GALT) Presents At 29th Annual ROTH Conference

Galectin Therapeutics' (GALT) CEO, Peter Traber on Q4 2016 Results - Earnings Call Transcript

Galectin Therapeutics Inc GALT Financial and Strategic SWOT Analysis Review [Updated: 15052017] Prices from USD $300

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a...

Galectin Therapeutics Inc GALT Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a...

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance

Activation of dectin-1-dependent signaling in macrophages through ligation by galectin 9 promotes an immunosuppressive, protumorigenic microenvironment in pancreatic adenocarcinoma (PDA). Blocking dectin 1 ligation restores anti-tumor immunity and delays tumor growth, thus offering a novel strategy for improving the effectiveness of immunotherapy in patients with PDA.

Galectin Therapeutics Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NORCROSS, Ga., Feb. 6, 2017 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the February 2nd presentation from Peter G. Traber, M.D, President, C...

BRIEF-Galectin Therapeutics has says can cover expenditures through 2017 - SEC filing

* Has generated sufficient financing to cover currently planned expenditures through 2017 - sec filing

Galectin 1 14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 o

Galectin 1 14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1 Pipeline Review, H2 2016SummaryGlobal Markets Direct's, Galectin 1 14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside ...

Bidding War For Galectin Inhibitors May Heat Up With GTCBio Conference

Galectin Therapeutics Inc GALT Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 20032017] Prices from USD $250

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a...

Galectin Therapeutics Inc GALT Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 25042017] Prices from USD $250

SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a...

Autoimmune Disease Patent Granted To Galectin

  Life Sciences Jobs   ...

Patent For Reducing Inflammatory Response Granted To Galectin

  Life Sciences Jobs   ...

Galectin Announces Important Milestones Towards Completion Of NASH CX Trial

  Life Sciences Jobs   ...

Galectin???s GR-MD-02 Demonstrates Efficacy In Patients With Moderate To Severe Plaque Psoriasis

  Life Sciences Jobs   ...

Galectin Reports 2017 First Quarter Financial Results And Provides Business Update

  Life Sciences Jobs   ...

Galectin Receives Notice Of Japanese Decision To Grant A Composition Of Matter Patent For GR-MD-02

  Life Sciences Jobs   ...

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017 [Updated: 20062017] Prices from

Galectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3 Pipeline Review, H1 2017SummaryGalectin 3 35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Protei...

Galectin Launches /i>, An Online Community And Publication On Liver Health And Liver Disease

  Life Sciences Jobs   ...

Galectin Therapeutics Submits Fast Track Application to FDA for GR-MD-02 in Treatment of Fatty Liver Disease with Advanced Fibrosis

NORCROSS, Ga., July 1, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it has submitted a Fast Track application to the FDA to help expedite its clinical development program of GR-MD-02 in the treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease...


Quick Search
Advertisement
 

News Quicklinks